Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation

Study includes 5 visits, when all basic clinical information, vital signs, symptoms, and side effects are going to be assessed at each appointment. Patients are going to be assigned by the computer, to receive an active or non-active drug for 14 days in a first phase. The order will be change during the second phase. The 2 weeks break without our medication will separate these phases. A very close observation regarding safety of our subjects will be implemented by study personnel and clinical investigators.

NCT Number	NCT03119584
Lead Sponsor	Texas Tech University Health Sciences Center, El Paso
Conditions	Chronic Constipation, Diabete Mellitus
Enrollment	23 participants
Start Date	2015-09-01
Primary Completion	2026-10 (estimated)
Study Completion	2027-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-03